Table 1.
Characteristics of the Sample at Clinical High-Risk for Psychosis (CHR-P)
| All CHR-P individuals | |
| Age, years, mean (SD) | 20.75 (4.74) |
| Female Sex, number (%) | 631 (47.09%) |
| SIPS Positive Symptoms Score, mean (SD)a | 10.93 (4.66) |
| CAARMS Positive Symptoms Scores, mean (SD)b | 10.37 (4.03) |
| IQ, mean z-score (SD)c | −0.21 (1.00) |
| Prescribed Antipsychotic Medication, number (%)d | 243 (18.63%) |
| Months of follow-up, mean (SD)e | 19.71 (13.97) |
| Converters, N (%)e | 157 (14.31%) |
| CHR-P individuals that converted to a psychotic disorder | |
| Age, years, mean (SD) | 20.09 (4.68) |
| Female Sex, number (%) | 64 (40.76%) |
| SIPS Positive Symptoms Score, mean (SD)f | 12.12 (5.06) |
| CAARMS Positive Symptoms Scores, mean (SD)f | 10.71 (4.24) |
| IQ, mean z-score (SD)g | −0.29 (1.03) |
| Prescribed Antipsychotic Medication, number (%)h | 32 (20.38%) |
CAARMS = Comprehensive Assessment of At-Risk Mental States; SIPS = Structured Interview for Psychosis-risk Syndromes; SD = standard Deviation. Positive symptom ratings at the time of scanning were available for the entire sample (N = 1340), assessed either with SIPS or CAARMS;
SIPS was used to assess CHR-P status in 806 CHR-P participants
CAARMS was used to assess CHR-P status in 534 CHR-P participants
Estimates of IQ were available in 924 CHR-P participants; z-scores were used to accommodate site differences in the instruments used (eTable 1)
Medication status at the time of scanning was available in 1304 CHR-P individuals
Conversion status was known for 1097 CHR-P participants but information about the length of the follow-up period was available for 975 CHR-P individuals
SIPS and CAARMS were respectively used to assess 115 and 42 individuals who converted
IQ estimates were available in 109 CHR-P individuals that converted
Medication status was available in 157 CHR-P individuals that converted